Dévina C. Ung

Dr. Dévina C. Ung

iBrain UMR 1253, Université de Tours, Inserm, France
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2017 in Molecular Psychiatry
Verified
Journal Article
Open access
DUDévina C. Ung
Dévina C. Ung
GIG Iacono
G Iacono
HMH Méziane
H Méziane
EBE Blanchard
E Blanchard
MPM-A Papon
M-A Papon
FLFrédéric Laumonnier
Frédéric Laumonnier
Synapse development and neuronal activity represent fundamental processes for the establishment of cognitive function. Structural organization as well as signalling pathways from receptor stimulation to gene expression regulation are mediated by synaptic activity and misregulated in neurodevelopmental disorders such as autism spectrum disorder (ASD) and intellectual disability (ID). Deleterious mutations in the PTCHD1 (Patched domain containing 1) gene have been described in male patients with X-linked ID and/or ASD. The structure of PTCHD1 protein is similar to the Patched (PTCH1) receptor; however, the cellular mechanisms and pathways associated with PTCHD1 in the developing brain are poorly determined. Here we show that PTCHD1 displays a C-terminal PDZ-binding motif that binds to the postsynaptic proteins PSD95 and SAP102. We also report that PTCHD1 is unable to rescue the canonical sonic hedgehog (SHH) pathway in cells depleted of PTCH1, suggesting that both proteins are involved in distinct cellular signalling pathways. We find that Ptchd1 deficiency in male mice (Ptchd1-/y) induces global changes in synaptic gene expression, affects the expression of the immediate-early expression genes Egr1 and Npas4 and finally impairs excitatory synaptic structure and neuronal excitatory activity in the hippocampus, leading to cognitive dysfunction, motor disabilities and hyperactivity. Thus our results support that PTCHD1 deficiency induces a neurodevelopmental disorder causing excitatory synaptic dysfunction.

1 December 2021 in Biological Psychiatry
Verified
Journal Article
Open access
ABAndrea Boitnott
Andrea Boitnott
MGMarta Garcia-Forn
Marta Garcia-Forn
DUDévina C. Ung
Dévina C. Ung
KNKristi Niblo
Kristi Niblo
DMDanielle Mendonca
Danielle Mendonca
SRSilvia De Rubeis
Silvia De Rubeis
Mutations in the X-linked gene DDX3X account for approximately 2% of intellectual disability in females, often comorbid with behavioral problems, motor deficits, and brain malformations. DDX3X encodes an RNA helicase with emerging functions in corticogenesis and synaptogenesis. We generated a Ddx3x haploinsufficient mouse (Ddx3x+/- females) with construct validity for DDX3X loss-of-function mutations. We used standardized batteries to assess developmental milestones and adult behaviors, as well as magnetic resonance imaging and immunostaining of cortical projection neurons to capture early postnatal changes in brain development. Ddx3x+/- females showed physical, sensory, and motor delays that evolved into behavioral anomalies in adulthood, including hyperactivity, anxiety-like behaviors, cognitive impairments in specific tasks (e.g., contextual fear memory but not novel object recognition memory), and motor deficits. Motor function declined with age but not if mice were previously exposed to behavioral training. Developmental and behavioral changes were associated with a reduction in brain volume, with some regions (e.g., cortex and amygdala) disproportionally affected. Cortical thinning was accompanied by defective cortical lamination, indicating that Ddx3x regulates the balance of glutamatergic neurons in the developing cortex. These data shed new light on the developmental mechanisms driving DDX3X syndrome and support construct and face validity of this novel preclinical mouse model.

6 March 2014
Verified
Journal Article
Open access
QXQing Xie
Qing Xie
DUDévina C. Ung
Dévina C. Ung
KKKamil Khafizov
Kamil Khafizov
AFAndras Fiser
Andras Fiser
ACAles Cvekl
Ales Cvekl
Pax6 is a key regulatory gene for eye, brain, and pancreas development. It acts as a transcriptional activator and repressor. Loss-of-function of Pax6 results in down- and upregulation of a comparable number of genes, although many are secondary targets. Recently, we found a prototype of a Pax6-binding site that acts as a transcriptional repressor. We also identified the Trpm3 gene as a Pax6-direct target containing the miR-204 gene located in intron 6. Thus, there are multiple Pax6-dependent mechanisms of transcriptional repression in the cell. More than 50 Pax6 missense mutations have been identified in humans and mice. Two of these mutations, N50K (Leca4) and R128C (Leca2), were analyzed in depth resulting in different numbers of regulated genes and different ratios of down- and upregulated targets. Thus, additional studies of these mutants are warranted to better understand the molecular mechanisms of the mutants’ action. Mutations in PAX6 and PAX6(5a), including G18W, R26G, N50K, G64V, R128C, and R242T, were generated with site-directed mutagenesis. A panel of ten luciferase reporters driven by six copies of Pax6-binding sites representing a spectrum of sites that act as repressors, moderate activators, and strong activators were used. Two additional reporters, including the Pax6-regulated enhancer from mouse Trpm3 and six copies of its individual Pax6-binding site, were also tested in P19 cells. PAX6 (N50K) acted either as a loss-of-function or neutral mutation. In contrast, PAX6 (R128C) and (R242T) acted as loss-, neutral, and gain-of-function mutations. With three distinct reporters, the PAX6 (N50K) mutation broke the pattern of effects produced by substitutions in the surrounding helices of the N-terminal region of the paired domain. All six mutations tested acted as loss-of-function using the Trpm3 Pax6-binding site. These studies highlight the complexity of Pax6-dependent transcriptional activation and repression mechanisms, and identify the N50K and R128C substitutions as valuable tools for testing interactions between Pax6, Pax6 (N50K), and Pax6 (R128C) with other regulatory proteins, including chromatin remodelers.

28 February 2024 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
DUDévina C. Ung
Dévina C. Ung
NPNicolas Pietrancosta
Nicolas Pietrancosta
EBElena Baz Badillo
Elena Baz Badillo
BRBrigitt Raux
Brigitt Raux
DTDaniel Tapken
Daniel Tapken
FLFrédéric Laumonnier
Frédéric Laumonnier
The ionotropic glutamate delta receptor GluD1, encoded by the GRID1 gene, is involved in synapse formation, function, and plasticity. GluD1 does not bind glutamate, but instead cerebellin and D-serine, which allow the formation of trans-synaptic bridges, and trigger transmembrane signaling. Despite wide expression in the nervous system, pathogenic GRID1 variants have not been characterized in humans so far. We report homozygous missense GRID1 variants in five individuals from two unrelated consanguineous families presenting with intellectual disability and spastic paraplegia, without (p.Thr752Met) or with (p.Arg161His) diagnosis of glaucoma, a threefold phenotypic association whose genetic bases had not been elucidated previously. Molecular modeling and electrophysiological recordings indicated that Arg161His and Thr752Met mutations alter the hinge between GluD1 cerebellin and D-serine binding domains and the function of this latter domain, respectively. Expression, trafficking, physical interaction with metabotropic glutamate receptor mGlu1, and cerebellin binding of GluD1 mutants were not conspicuously altered. Conversely, upon expression in neurons of dissociated or organotypic slice cultures, we found that both GluD1 mutants hampered metabotropic glutamate receptor mGlu1/5 signaling via Ca2+ and the ERK pathway and impaired dendrite morphology and excitatory synapse density. These results show that the clinical phenotypes are distinct entities segregating in the families as an autosomal recessive trait, and caused by pathophysiological effects of GluD1 mutants involving metabotropic glutamate receptor signaling and neuronal connectivity. Our findings unravel the importance of GluD1 receptor signaling in sensory, cognitive and motor functions of the human nervous system.

1 October 2018 in Clinica Chimica Acta
Verified
Journal Article
Closed access
MVM.-L. Vuillaume
M.-L. Vuillaume
BCB. Cogné
B. Cogné
MJMédéric Jeanne
Médéric Jeanne
ABA. Boland
A. Boland
DUDévina C. Ung
Dévina C. Ung
ATAnnick Toutain
Annick Toutain

27 July 2025 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Open access
DUDévina C. Ung
Dévina C. Ung
Stéphane MartinStéphane Martin
Stéphane Martin
YHYann Herault
Yann Herault
FLFrédéric Laumonnier
Frédéric Laumonnier
Neurodevelopmental disorders (NDDs) encompass a broad spectrum of conditions, including intellectual disability (ID), Attention Deficit Hyperactivity Disorders (ADHD) and autism spectrum disorders (ASD), often linked to disrupted synaptic functionality. Among the major NDD genes, PTCHD1 (Patched Domain Containing 1) encodes a transmembrane protein which acts as a crucial regulator of synaptic function. Mutations and microdeletions in PTCHD1 have been associated with global developmental delays such as ID, ASD, and behavioral abnormalities. This review explores the neurodevelopmental functions of PTCHD1, particularly its position within the synaptic environment, from the association with the postsynaptic proteome to the regulation of several major neuronal signaling pathways, cholesterol homeostasis and receptor trafficking. In a pathophysiological context, studies in Ptchd1 knockout mouse models revealed abnormal behavioral phenotypes, linked to synaptic impairments, including reduced excitatory postsynaptic currents and altered dendritic morphology similarly to recent results on human-derived neuronal models. By synthesizing findings from genetic, molecular, and behavioral studies, this review underscores the multifaceted roles of PTCHD1 in neurodevelopment and synaptic regulation. Understanding its function in synaptic pathways may provide crucial insights into the pathophysiology of NDDs, emphasizing the need for further research to clarify its role as a potential synaptic, orphan receptor.